07 October 2019

 

Sensyne Health signs major agreements with a Fortune 200 healthcare company and a data infrastructure specialist to launch and scale its digital health products in the U.S.

 

Oxford, UK; 07 October 2019: Sensyne Health plc (LSE: SENS), (“Sensyne Health” or “the Company”), the British clinical AI technology company, today announced it has signed agreements with a Fortune 200 company and a data infrastructure specialist to launch and scale its digital health products under licence in the U.S. 

 

The initial focus will be on taking Sensyne Health’s gestational diabetes product, GDm-Health, to the U.S. market. With nearly 10 percent of pregnancies in the U.S. affected by GDM every year, Sensyne Health’s product can dramatically change the way this treatable condition is diagnosed and managed by doctors and their patients.  This will be followed by Sensyne Health’s chronic disease products for respiratory, EDGE, and cardiovascular, Support-HF.

 

As part of these agreements, Sensyne Health will be developing Clinical AI-as-a-service solutions that will use artificial intelligence (AI) and predictive analytics to help prevent and manage a variety of chronic health conditions.

 

Sensyne Health collaborates with the U.K.’s National Health Service (NHS) to develop and scale digital health applications that employ AI and anonymised patient data to detect warning signs for various clinical conditions. The first solution, GDm-Health, is in production in the U.K. and is currently being beta-tested in the U.S. by the Fortune 200 Company and a major regional healthcare network. GDm-Health gives patients greater insight into their personal health data, offers expectant mothers diagnosed with GDM greater control over the management of their condition and gives clinicians valuable insight to more efficiently and proactively manage care. To date, clinical trial data in the U.K. has shown that GDm-Health improves diagnosis and treatment, leading to improved outcomes for mothers and their babies.1

 

While initially focused on GDM, the three companies plan to continue to expand Clinical-AI-as-a-Service offerings to include other medical conditions via a compliant, secure, cloud-based service that safeguards patient privacy. More information on this new partnership will be announced at the time of its official launch.

 

“We are delighted that this innovative trans-Atlantic relationship will lead to the expansion of our digital healthcare applications to U.S. patients and providers,” said Lord (Paul) Drayson, CEO of Sensyne Health. “By working with these partners, we will be able to accelerate the full potential of these applications which were originally invented in the NHS. We are also delighted that these major agreements mark the completion of the last remaining milestone objective that we set at the time of our IPO in August 2018. All our objectives set at that time have now been achieved.”

 

-ENDS-

 

Reference

1Mackillop, L., Hirst, J.E., Bartlett, K.J., Birks, J.S., Clifton, L., Farmer, A.J., Gibson, O., Kenworthy, Y., Levy, J.C., Loerup, L. and Rivero-Arias, O. Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System with Standard Clinic Care in Women with Gestational Diabetes: Randomized Controlled Trial. JMIR mHealth and uHealth, 6(3), p.e71. 2018.

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

 

Lorimer Headley, Chief Financial Officer

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden

 

James Steel

 

Oliver Jackson

 

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

sensynehealth@consilium-comms.com

 

 

 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

 

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

 


Back to previous page